La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Vera Therapeutics Gestione

Gestione criteri di controllo 4/4

Vera Therapeutics' Il CEO è Marshall Fordyce, nominato in May2016, e ha un mandato di 8.25 anni. la retribuzione annua totale è $ 3.43M, composta da 17.1% di stipendio e 82.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.42% delle azioni della società, per un valore di $ 8.63M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 3.8 anni.

Informazioni chiave

Marshall Fordyce

Amministratore delegato

US$3.4m

Compenso totale

Percentuale dello stipendio del CEO	17.1%
Mandato del CEO	8.3yrs
Proprietà del CEO	0.3%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Marshall Fordyce rispetto agli utili di Vera Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$94m
Dec 31 2023	US$3m	US$586k	-US$96m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$107m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$551k	-US$89m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$45m
Dec 31 2021	US$1m	US$479k	-US$33m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$3m	US$360k	-US$53m

Compensazione vs Mercato: La retribuzione totale di Marshall ($USD 3.43M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Marshall è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Marshall Fordyce (49 yo)

8.3yrs

Mandato

US$3,429,733

Compensazione

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Marshall Fordyce	Founder	8.3yrs	US$3.43m	0.33% $ 7.8m
Sean Grant	Chief Financial Officer	3.2yrs	US$1.76m	0.041% $ 981.3k
David Johnson	Chief Opearating Officer	less than a year	Nessun dato	Nessun dato
Joseph Young	Senior VP of Finance & Chief Accounting Officer	3.3yrs	Nessun dato	0.035% $ 839.8k
Julien Capers	Senior Vice President of Legal	2.7yrs	Nessun dato	Nessun dato
Kelly Rauber	Senior Vice President of Human Resources	2.7yrs	Nessun dato	Nessun dato
Tom Doan	Senior Vice President of Development Operations	4.5yrs	Nessun dato	Nessun dato
Lauren Frenz	Chief Business Officer	7.1yrs	Nessun dato	Nessun dato
Neeraj Pakala	Senior VP and Head of Product Development & Manufacturing	1.8yrs	Nessun dato	Nessun dato
Kerry Cooper	Senior Vice President of Medical Affairs	1.3yrs	Nessun dato	Nessun dato
Robert Brenner	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
William Turner	Chief Development Officer	less than a year	Nessun dato	Nessun dato

2.7yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di VERA è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Marshall Fordyce	Founder	8.3yrs	US$3.43m	0.33% $ 7.8m
Maha Katabi	Independent Director	3.9yrs	US$153.63k	0% $ 0
Michael Morrissey	Independent Chairman of the Board	2.3yrs	US$187.13k	0% $ 0
Patrick Gerald Enright	Independent Director	3.9yrs	US$155.63k	0% $ 0
Beth Seidenberg	Independent Director	8.3yrs	US$153.13k	0.27% $ 6.5m
Scott William Morrison	Independent Director	4.4yrs	US$160.63k	0% $ 0
Andrew Cheng	Independent Director	7.3yrs	US$154.63k	0.032% $ 759.8k
Christy Oliger	Director	less than a year	Nessun dato	0.0054% $ 129.8k
Kimball Hall	Independent Director	2.8yrs	US$152.04k	0% $ 0

3.9yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VERA sono considerati esperti (durata media dell'incarico 3.8 anni).

Vera Therapeutics Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Recent updates

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Independent Chairman of the Board recently bought US$215k worth of stock

Vera Therapeutics, Inc. has completed an IPO in the amount of $47.85 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente